Welcome to Sun-shine chemical
+86-27-65522453 sales@sun-shinechem.com

Daridorexant ( ACT541468 )

Catalog No.: 20265
Cas No.: 1505484-82-1
Purity : ≧98.0%

Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia. Daridorexant reduces overactive wakefulness associated with insomnia by blocking the activity of orexin. 

For research use only. We do not sell to patients.

Chemical Information

NameDaridorexant ( ACT541468 )
Iupac Chemical NameMethanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)-
SynonymsDaridorexant ; ACT541468 ; ACT 541468 ; ACT-541468
Molecular FormulaC23H23ClN6O2
Molecular Weight450.92
SmileO=C(N1[C@](C)(C2=NC3=CC=C(Cl)C(C)=C3N2)CCC1)C4=CC(OC)=CC=C4N5N=CC=N5
InChiKeyNBGABHGMJVIVBW-QHCPKHFHSA-N
InChiInChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1
CAS Number1505484-82-1
Related CAS1505484-82-1

Ordering Information

PackagingPriceAvailabilityPurityShipping Time
BulkEnquiryEnquiryEnquiry
Request Bulk Quote Download MSDS Tel : +86-27-65522453   Email : sales@sun-shinechem.com
FormulationOff-white solid
Purity≧98.0%
StorageDry, dark and at 0-4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
SolubilitySoluble in DMSO
HandlingRefer to MSDS operation
Shipping ConditionShipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
HS Code2934200090
Coming soon.
Targets dual orexin receptor antagonist (DORA)
Mechanism
Cell study
Animal study
Clinical study

1: Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Ann Neurol. 2020 Mar;87(3):347-356. doi: 10.1002/ana.25680. Epub 2020 Feb 5. Erratum in: Ann Neurol. 2020 Sep;88(3):647-651. PMID: 31953863.

2: Zammit G, Dauvilliers Y, Pain S, Sebök Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020 May 26;94(21):e2222-e2232. doi: 10.1212/WNL.0000000000009475. Epub 2020 Apr 27. PMID: 32341187.

3: Molano JRV. Daridorexant: A new medication for insomnia in older adults? Neurology. 2020 May 26;94(21):e2287-e2289. doi: 10.1212/WNL.0000000000009489. PMID: 32451342.

4: Zenklusen I, Muehlan C, Ulc I, Liška J, Dingemanse J. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. Clin Exp Pharmacol Physiol. 2020 Nov;47(11):1843-1849. doi: 10.1111/1440-1681.13370. Epub 2020 Jul 21. PMID: 32603512.

5: Berger B, Brooks S, Zuiker R, Richard M, Muehlan C, Dingemanse J. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS Drugs. 2020 Dec;34(12):1253-1266. doi: 10.1007/s40263-020-00768-8. Epub 2020 Nov 18. PMID: 33205362.

6: Boof ML, Dingemanse J, Lederer K, Fietze I, Ufer M. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep. 2020 Dec 11:zsaa275. doi: 10.1093/sleep/zsaa275. Epub ahead of print. PMID: 33305817.

7: Erratum to "Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder". Ann Neurol. 2020 Sep;88(3):647-651. doi: 10.1002/ana.25801. Epub 2020 Jul 1. Erratum for: Ann Neurol. 2020 Mar;87(3):347-356. PMID: 33464656.

8: Muehlan C, Zuiker R, Peeters P, Rowles R, Dingemanse J. Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects. J Clin Psychopharmacol. 2020 Mar/Apr;40(2):157-166. doi: 10.1097/JCP.0000000000001182. PMID: 32134851.

9: Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. ChemMedChem. 2020 Dec 3;15(23):2286-2305. doi: 10.1002/cmdc.202000453. Epub 2020 Oct 28. PMID: 32937014.

10: Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1063-1078. doi: 10.1080/17425255.2020.1817380. Epub 2020 Oct 4. PMID: 32901578.


Chemical Structure

20265 - Daridorexant ( ACT541468 ) | CAS 1505484-82-1

Quick inquiry

Change